Salla et al. (2018) identified and characterized two novel RIPK2 inhibitors by using molecular modeling and chemoinformatics analysis (Salla et al., 2018). The degree of suppression in DSS-induced colitis was significantly greater in mice treated with these RIPK2 inhibitors than in those treated with gefitinib (Salla et al., 2018). This evidence concerns the gene RIPK2 and colitis.